- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 28.05. | TransCode Therapeutics appoints RNA expert to advisory board | 9 | Investing.com | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.05. | TransCode Therapeutics beruft RNA-Experten in den Beirat | 6 | Investing.com Deutsch | ||
| 08.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 169 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| 05.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 268 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
| 02.05. | TransCode Therapeutics approves reverse stock split to meet Nasdaq rules | 2 | Investing.com | ||
| 02.05. | TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall | 2 | Seeking Alpha | ||
| 02.05. | TransCode Therapeutics genehmigt Aktienzusammenlegung zur Einhaltung der NASDAQ-Regeln | 3 | Investing.com Deutsch | ||
| 02.05. | Transcode Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 136 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen | |
| 01.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer | 113 | PR Newswire | A total of 13 patients treated with four escalating doses of TTX-MC138
No significant safety or dose limiting toxicities reported
Two patients have so far maintained... ► Artikel lesen | |
| 01.05. | EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug | 3 | Benzinga.com | ||
| 30.04. | Transcode Therapeutics, Inc. - 10-K/A, Annual Report | 4 | SEC Filings | ||
| 21.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | 13 | SEC Filings | ||
| 15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | 6 | SEC Filings | ||
| 31.03. | Transcode Therapeutics, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 5 | SEC Filings | ||
| 27.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 191 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
| 25.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | TransCode Therapeutics Announces $10M Stock And Warrant Offering | 1 | RTTNews | ||
| 24.03. | TransCode Therapeutics stock slides after announces to raise $10M securities offering | 5 | Seeking Alpha |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 97,10 | +0,21 % | BioNTech: Ryan Richardson verlässt Vorstand im Herbst | Bei BioNTech steht ein Wechsel im Vorstand bevor. Ryan Richardson wird seine Position als Chief Strategy Officer sowie seine Ämter in Tochtergesellschaften der BioNTech-Gruppe zum 30. September 2025... ► Artikel lesen | |
| QIAGEN | 43,645 | +2,14 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| NOVAVAX | 6,511 | -2,16 % | Novavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study | Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,329 | +35,39 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| BRAIN BIOTECH | 2,220 | -2,20 % | Brain Biotech +30%: Das ist der Grund! | Die Aktie der Brain Biotech AG explodiert heute wie aus dem Nichts. Wir kennen die Hintergründe zum Kursspektakel und haben gleich bessere Tipps parat. Aktuell rund 30% bis auf über 2,50 € geht es für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,250 | -6,02 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,260 | -5,23 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
| XOMA ROYALTY | 22,000 | 0,00 % | ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction | SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,510 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| T2 BIOSYSTEMS | 0,075 | -36,78 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| ORAGENICS | 1,490 | 0,00 % | Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development | SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| VIVUS | - | - | Vivus' Qsymia gains market approval in UAE for obesity treatment |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,220 (-1,96 %) liegt der Kurs bei 11,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.